Analytical Data
-
Gene name
SMN
- Application
-
Alternative Names
BCD541; SMA1; SMN1; SMA2; SMA3; SMA4; SMNT; T-BCD541; SMNC; Gemin-1; Survival Of Motor Neuron 1, Telomeric; Component of gems 1; Spinal Muscular Atrophy(Werdnig-Hoffmann Disease,Kugelberg-Welander Dis
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16637
-
Expression Region
Ala2~Asn294
-
Molecular Weight
39kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of SMN (Survival of Motor Neuron) recombinant protein has garnered significant attention due to its critical role in spinal muscular atrophy (SMA), a debilitating neurodegenerative disorder characterized by the loss of motor neurons in the spinal cord. SMN is essential for the assembly of small nuclear ribonucleoproteins (snRNPs), which are crucial for pre-mRNA splicing and overall cellular function. Mutations in the SMN1 gene lead to a deficiency in SMN protein levels, resulting in progressive muscle weakness and atrophy. Research efforts have focused on understanding the molecular mechanisms underlying SMN function, the pathophysiology of SMA, and the potential for therapeutic interventions. The recombinant production of SMN protein has enabled detailed studies of its structure, function, and interaction with other cellular components. Moreover, advances in gene therapy and small molecule drugs aimed at increasing SMN levels or enhancing its activity have emerged as promising strategies to combat SMA. Utilizing SMN recombinant proteins in laboratory settings has facilitated the development of assays and models to test these therapeutic approaches, ultimately aiming to improve outcomes for individuals affected by this condition. As research continues, a deeper understanding of SMN's role in the disease process holds the potential to unlock new avenues for effective treatments, thereby addressing the urgent medical needs of those living with spinal muscular atrophy.
